Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 6Recruiting 3Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2

Conditions

Multiple Myeloma 495Lymphoma 52Recurrence 50Neoplasms, Plasma Cell 49Immunoglobulin Light-chain Amyloidosis 43Neoplasms 35Lymphoma, Non-Hodgkin 35Leukemia 34Hematologic Neoplasms 32Myelodysplastic Syndromes 28Smoldering Multiple Myeloma 27Leukemia, Myeloid, Acute 26Leukemia, Plasma Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Monoclonal Gammopathy of Undetermined Significance 18Hodgkin Disease 18Leukemia, Lymphocytic, Chronic, B-Cell 17Amyloidosis 17Lymphoma, B-Cell 15Breast Neoplasms 14Ovarian Neoplasms 12Paraproteinemias 11Myeloproliferative Disorders 10Colorectal Neoplasms 10Primary Myelofibrosis 9Melanoma 9Lymphoma, Follicular 9Infections 9Prostatic Neoplasms 8Lymphoproliferative Disorders 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Hemorrhagic Disorders × Plasma cell × Clear all
NCT06963216 2026-05-11

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Kedrion S.p.A.

Phase 3 Recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT06644443 2024-10-16

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Shenzhen University General Hospital

Phase 1/2 Recruiting
10 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT06271252 2024-08-02

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

OriCell Therapeutics Co., Ltd.

Phase 1 Recruiting
81 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡